-
Most Recent
Search Results
240 results for frx
Why June 30 Could Trigger a Private Credit Reckoning
Today, Louis is joining us to explain why a key deadline — June 30 — could force long-hidden problems into the open. That’s when certain…
Will the Worst-Case Scenario Unfold Tonight?
U.S. strikes military targets on Iran’s key oil island… Trump warns “a whole civilization will die tonight”… Luke Lango’s framework for what comes next… and…
Pharmaceutical Companies Hit New Highs, Solar Stocks New Lows
Solar stocks are among the investments hitting new 52 week lows today in the stock market as pharmaceutical companies hit new highs.
Longtime Vanguard Health Care Manager Owens to Retire
Vanguard announced Wednesday that longtime Vanguard Health Care manager Edward Owens will be stepping down at the end of 2012.
2014’s 10 Best Stocks in the S&P 500
Don’t let the S&P 500’s weak 2014 performance fool you — the blue-chip index’s best stocks are a jumpy crowd that cruised 20%-50% in just…
Hertz (HTZ) Gives Carl Icahn 3 Board Seats to Avoid Proxy Battle
Hertz shares rise as the car rental company agrees to give activist investor Carl Icahn 3 board seats.
The Market Rally Resembles a Dog On a Bone
To this point in the year stocks, bonds, gold, oil and gas markets are working just fine, and my charts suggest more to come. Read…
41 S&P 500 Stocks Hit New Lows in Early Tuesday Trading
S&P 500 dips slightly Tuesday, with Urban Outfitters, Abercrombie & Fitch and Citigroup among losers by midday.
Every Crisis Has a Hidden Trade: Here’s Where the Smart Money Goes Next
When most investors hear the word “crisis,” they think about danger. But every crisis on Wall Street has another side: Opportunity.
MRK: Merck Sells Consumer Business to Double Down on Blockbusters
Swinging for the fences, MRK sold one of the industry’s crown jewels in exchange for an opportunity to find new blockbuster drugs. It’s a risky…
Is Big Pharma Resistant to Antibiotics?
Less profitable drugs take a backseat despite health risks
Actavis Prescribes Profits via M&A and Generic Drugs
This specialty pharmaceutical company is consolidating its way into becoming a post-Affordable Care Act powerhouse.
No Payday In Sight for Alzheimer’s Drug Stocks
At best, the drugs on the market are stopgap measures. They can’t cure the disease.
Is it Time to Follow Ichan Out of Amgen — and Other Biotechs?
Investor Carl Ichan recently dumped several biotechs. However, Amgen’s sales are strong, and with other positives, it’s possible he cut bait too soon.
Johnson & Johnson, Forest Labs Will Make You Sick
Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both…
2 Biotech Stocks to Buy After Earnings
Actavis (ACT) and Jazz Pharmaceuticals (JAZZ) reported outstanding Q3 earnings and are strong biotech stocks to buy.
Why We’re Ignoring Oil Prices and Buying Energy Stocks Instead
We can’t predict the exact contours of energy markets. A handful of individuals are now dictating where oil prices go, and even they don’t seem…
Wall Street’s 10 Biggest Deals of Q1 2014
The year is off to a hot start for M&A, as Facebook, Google, IBM and others got busy pulling off Q1’s biggest deals.
3 Mutual Funds Poised to Profit From Obamacare
By Bill Wysor — There are winners and losers in the changing healthcare industry, but let seasoned mutual fund managers do the legwork for you.
Buy Icahn Enterprises to Play Apple Stock with Less Risk
For a low-risk way to play a bounce back in Apple stock, let Carl Icahn and a bet on Icahn Enterprises stock lead the way.
4 Best Mutual Funds at Vanguard Now
Here are four of the top mutual fund investments from Vanguard now.
The 60/40 Portfolio Was Built for a World That No Longer Exists
Resource sovereignty is reshaping markets, inflation, and investing – favoring energy, minerals, and real assets over globalized tech.
6 – 10 of 240 results
